Panulisib

Panulisib (P7170; AK151761) is an orally active inhibitor of PI3K (IC50 = 2.2 nM) and mTOR (IC50 = 4.4 nM) . Panulisib inhibits ALK1 and DNA-PK, two enzymes that respectively participate in angiogenesis and DNA repair, with IC50 values of 47 nM and 1.5 nM respectively. Panulisib inhibits cell proliferation and apoptosis. Panulisib can be used for research on breast cancer and non-small cell lung cancer[1][2][3].

Product Specifications

CAS Number

[1356033-60-7]

Product Name Alternative

P7170; AK151761

UNSPSC

12352005

Target

Anaplastic lymphoma kinase (ALK) ; Apoptosis; DNA-PK; mTOR; PI3K

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

N#C/N=C(N1C2=CC=C(C(C)(C#N)C)N=C2)\N(C)C3=C1C4=CC(C5=CC(C(F)(F)F)=C(N)N=C5)=CC=C4N=C3

Molecular Formula

C27H20F3N9

Molecular Weight

527.50

References & Citations

[1]Jalota-Badhwar A, et al. P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity. Mol Cancer Ther. 2015 May;14 (5) :1095-106.|[2]Bean JR, et al. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat. 2015 Jan;149 (1) :69-79. |[3]Venkatesha VA, et al. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer. Mol Cancer. 2014 Dec 2;13:259.